利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.041 秒)

    SUBSTITUTED ISOXAZOLE COMPOUNDS
    1.
    发明申请
    SUBSTITUTED ISOXAZOLE COMPOUNDS 有权
    取代的异丙唑化合物

    公开(公告)号：US20110300165A1

    公开(公告)日：2011-12-08

    申请号：US13145730

    申请日：2010-01-22

    申请人： Scott Hunter Watterson ,  Alaric J. Dyckman ,  William J. Pitts ,  Steven H. Spergel

    发明人： Scott Hunter Watterson ,  Alaric J. Dyckman ,  William J. Pitts ,  Steven H. Spergel

    IPC分类号： A61K31/4245 ,  A61P29/00 ,  A61P37/06 ,  A61P19/02 ,  A61P25/00 ,  A61P17/06 ,  A61P11/06 ,  C07D413/14 ,  A61P3/10

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

    摘要翻译： 公开了式（I）化合物或其药学上可接受的盐，其中Q为R 1为烷基或芳基，所述芳基任选被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，-OR 4和/ 或卤素; 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫疾病和血管疾病）中的疾病或病症的进展。

    Substituted isoxazole compounds
    2.
    发明授权
    Substituted isoxazole compounds 有权
    取代的异恶唑化合物

    公开(公告)号：US08354398B2

    公开(公告)日：2013-01-15

    申请号：US13145730

    申请日：2010-01-22

    申请人： Scott Hunter Watterson ,  Alaric J. Dyckman ,  William J. Pitts ,  Steven H. Spergel

    发明人： Scott Hunter Watterson ,  Alaric J. Dyckman ,  William J. Pitts ,  Steven H. Spergel

    IPC分类号： A61K31/4245 ,  C07D413/14

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

    摘要翻译： 公开了式（I）化合物或其药学上可接受的盐，其中Q为R 1为烷基或芳基，所述芳基任选被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，-OR 4和/ 或卤素; 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫性疾病和血管疾病）中的疾病或病症的进展。

    SUBSTITUTED HETEROCYCLIC COMPOUNDS
    3.
    发明申请
    SUBSTITUTED HETEROCYCLIC COMPOUNDS 有权
    取代的杂环化合物

    公开(公告)号：US20120022041A1

    公开(公告)日：2012-01-26

    申请号：US13145721

    申请日：2010-01-22

    申请人： William J. Pitts ,  Alaric J. Dyckman ,  Steven H. Spergel ,  Scott Hunter Watterson

    发明人： William J. Pitts ,  Alaric J. Dyckman ,  Steven H. Spergel ,  Scott Hunter Watterson

    IPC分类号： A61K31/4439 ,  A61P37/06 ,  A61P29/00 ,  C07D413/14

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

    摘要翻译： 公开了式（I）化合物或其药学上可接受的盐，其中Q为R 1为环烷基，杂芳基或杂环基，各自任选被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，-OR 4， 和/或卤素; 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如血管疾病和自身免疫性疾病）中疾病或病症的发展。

    Substituted heterocyclic compounds
    4.
    发明授权
    Substituted heterocyclic compounds 有权
    取代的杂环化合物

    公开(公告)号：US08404672B2

    公开(公告)日：2013-03-26

    申请号：US13145721

    申请日：2010-01-22

    申请人： William J. Pitts ,  Alaric J. Dyckman ,  Steven H. Spergel ,  Scott Hunter Watterson

    发明人： William J. Pitts ,  Alaric J. Dyckman ,  Steven H. Spergel ,  Scott Hunter Watterson

    IPC分类号： A61K31/4402 ,  C07D413/14

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

    摘要翻译： 公开了式（I）化合物或其药学上可接受的盐，其中Q为R 1为环烷基，杂芳基或杂环基，各自任选被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，-OR 4， 和/或卤素; 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如血管疾病和自身免疫性疾病）中疾病或病症的发展。

    Substituted pyrazole compounds
    5.
    发明授权
    Substituted pyrazole compounds 有权
    取代的吡唑化合物

    公开(公告)号：US08389509B2

    公开(公告)日：2013-03-05

    申请号：US13145728

    申请日：2010-01-22

    申请人： Alaric J. Dyckman ,  William J. Pitts ,  Scott Hunter Watterson

    发明人： Alaric J. Dyckman ,  William J. Pitts ,  Scott Hunter Watterson

    IPC分类号： A61K31/4155 ,  A61K31/397 ,  A61K31/4245 ,  C07D231/10 ,  C07D271/06 ,  C07D205/04

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

    摘要翻译： 公开了式（I）的化合物或其药学上可接受的盐，其中：n为0或选自1至4的整数; R 1是环烷基，芳基，杂芳基或杂环基，各自任选地被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，苄基，-OR 4和/或卤素的取代基取代。 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫疾病和血管疾病）中的疾病或病症的进展。

    SUBSTITUTED PYRAZOLE COMPOUNDS
    6.
    发明申请
    SUBSTITUTED PYRAZOLE COMPOUNDS 有权
    取代的吡唑化合物

    公开(公告)号：US20110275610A1

    公开(公告)日：2011-11-10

    申请号：US13145728

    申请日：2010-01-22

    申请人： Alaric J. Dyckman ,  William J. Pitts ,  Scott Hunter Watterson

    发明人： Alaric J. Dyckman ,  William J. Pitts ,  Scott Hunter Watterson

    IPC分类号： A61K31/4245 ,  A61P29/00 ,  A61P37/00 ,  C07D413/14

    CPC分类号： C07D413/14

    摘要： Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

    摘要翻译： 公开了式（I）的化合物或其药学上可接受的盐，其中：n为0或选自1至4的整数; R 1是环烷基，芳基，杂芳基或杂环基，各自任选地被一至五个独立地选自C 1至C 6烷基，C 1至C 4卤代烷基，苄基，-OR 4和/或卤素的取代基取代。 并且R 2，R 3，R 4和n在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫疾病和血管疾病）中的疾病或病症的进展。